Form 4: Alector Principal Financial Officer Granted 18,000 Stock Options

Alector, Inc.'s Principal Financial Officer, Neil Lindsay Berkley, was granted 18,000 employee stock options with an exercise price of $1.42 per share.

Summary

• Neil Lindsay Berkley, Principal Financial Officer of Alector, Inc. (ALEC), was granted 18,000 employee stock options.
• The options have an exercise price of $1.42 per share.
• The earliest transaction date associated with this grant is July 1, 2025.
• The options expire on July 1, 2035.
• The vesting schedule dictates that one-third (1/3rd) of the total shares subject to the option shall vest on November 1, 2025, and one-twelfth (1/12th) of the total shares shall vest in equal monthly installments thereafter, with full vesting by July 1, 2026.
• Following this transaction, Neil Lindsay Berkley beneficially owns 18,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive sign for aligning management incentives with shareholder interests and retaining talent. It is a standard compensation practice.

Positives

• The grant of employee stock options to a key executive, the Principal Financial Officer, aligns management's interests with shareholder value creation.
• The structured vesting schedule encourages long-term retention and incentivizes sustained performance from the executive.

Negatives

• This option grant does not provide immediate cash inflow for the company.
• There is a potential for future dilution of existing shares if these options are exercised.

Risks

• If Alector's stock price remains below the exercise price of $1.42 per share, the options may become worthless, reducing their incentive value.
• The exercise of these options in the future could lead to dilution for current shareholders.

Future Outlook

The grant of stock options to a key executive suggests a long-term commitment to the company's future performance and aligns executive incentives with potential future stock price appreciation.

Industry Context

Granting stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for growth companies like Alector, Inc., to attract and retain talent, conserve cash, and incentivize long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the biotech industry, often used to align executive incentives with shareholder value creation.
• The vesting schedule, with a significant initial cliff and subsequent monthly vesting, is typical for retaining key personnel over several years.
• The exercise price being a specific value ($1.42) indicates it is likely tied to the stock price at the time of grant, a common practice for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value if executive incentives lead to improved company performance.
• Employees: Reflects standard executive compensation practices, which can be a positive signal for overall employee incentive programs.

Next Steps

• Neil Lindsay Berkley will continue to vest his stock options according to the defined schedule, with full vesting by July 1, 2026.
• The options can be exercised at any time after vesting until their expiration on July 1, 2035.

Key Dates

Recommendation

Keywords

Alector, ALEC, SEC Form 4, stock options, employee stock option, executive compensation, Neil Lindsay Berkley, Principal Financial Officer, equity grant, vesting schedule, insider transaction